BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 369 filers reported holding BIO-TECHNE CORP in Q4 2019. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $460,562 | -15.1% | 6,766 | +1.8% | 0.01% | -16.7% |
| Q2 2023 | $542,348 | +7.3% | 6,644 | -2.5% | 0.01% | 0.0% |
| Q1 2023 | $505,679 | -23.1% | 6,816 | -14.1% | 0.01% | -14.3% |
| Q4 2022 | $657,667 | +31.0% | 7,935 | +351.9% | 0.01% | +16.7% |
| Q3 2022 | $502,000 | -26.4% | 1,756 | -11.1% | 0.01% | -25.0% |
| Q2 2022 | $682,000 | -19.6% | 1,975 | +0.6% | 0.01% | -11.1% |
| Q1 2022 | $848,000 | -8.9% | 1,964 | +13.3% | 0.01% | 0.0% |
| Q4 2021 | $931,000 | +29.7% | 1,734 | +12.1% | 0.01% | +12.5% |
| Q3 2021 | $718,000 | -23.9% | 1,547 | -25.7% | 0.01% | -11.1% |
| Q2 2021 | $943,000 | -6.4% | 2,083 | -21.0% | 0.01% | -18.2% |
| Q1 2021 | $1,007,000 | +19.0% | 2,637 | -1.4% | 0.01% | +10.0% |
| Q4 2020 | $846,000 | +122.0% | 2,674 | +66.5% | 0.01% | +100.0% |
| Q3 2020 | $381,000 | -5.5% | 1,606 | +5.2% | 0.01% | -16.7% |
| Q2 2020 | $403,000 | +9.2% | 1,527 | -21.2% | 0.01% | +20.0% |
| Q1 2020 | $369,000 | -1.6% | 1,937 | +13.5% | 0.01% | 0.0% |
| Q4 2019 | $375,000 | -17.4% | 1,707 | -25.3% | 0.01% | -28.6% |
| Q3 2019 | $454,000 | – | 2,285 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |